Martinez-Fong, DanielBannon, Michael J.Trudeau, Louis-EricGonzalez-Barrios, Juan A.Arango-Rodriguez, Martha L.Hernandez-Chan, Nancy G.Reyes-Corona, DavidArmendáriz-Borunda, JuanNavarro-Quiroga, Ivan2021-10-042021-10-042012Nanomedicine: Nanotechnology, Biology, and Medicine , 2012, 8: 1052–1069http://dx.doi.org/10.1016/j.nano.2012.02.009http://hdl.handle.net/11447/4785Nanomedicine has focused on targeted neurotrophic gene delivery to the brain as a strategy to stop and reverse neurodegeneration in Parkinson's disease. Because of improved transfection ability, synthetic nanocarriers have become candidates for neurotrophic therapy. Neurotensin (NTS)-polyplex is a “Trojan horse” synthetic nanocarrier system that enters dopaminergic neurons through NTS receptor internalization to deliver a genetic cargo. The success of preclinical studies with different neurotrophic genes supports the possibility of using NTS-polyplex in nanomedicine. In this review, we describe the mechanism of NTS-polyplex transfection. We discuss the concept that an effective neurotrophic therapy requires a simultaneous effect on the axon terminals and soma of the remaining dopaminergic neurons. We also discuss the future of this strategy for the treatment of Parkinson's disease.enNeurorestorationNeuroprotectionNeurodegenerationRegenerationSurvivalArticle